FDA Approves Caplyta for Major Depressive Disorder, Offering New Hope
Johnson & Johnson's FDA approval of CAPLYTA (lumateperone) as an adjunctive treatment for major depressive disorder in adults offers a new hope for remission, demonstrating efficacy and a favorable safety profile based on Phase 3 trials, potentially transforming treatment expectations for depression.